A new report by Public Citizen found that of 147 patients’ groups that sided with the pharmaceutical industry against a Medicare Part B demonstration project designed to lower the prices of expensive drugs, at least 110 (75%) received funding from the industry. Continue reading Patients’ Groups and Big Pharma
In the year after the Supreme Court’s landmark antitrust decision in FTC v. Actavis, pharmaceutical companies entered into substantially fewer potential pay-for-delay patent dispute settlements, according to a new FTC staff report. In pay for delay, companies that hold patents for drugs pay other companies not to release similar drugs. The report summarizes data on patent settlements – which can arise between brand and generic drug companies – filed with the FTC and the Department of Justice during FY 2014 under the Medicare Modernization Act of 2003. Generic drugs often cost less than brand drugs, helping to make medicines affordable for millions of American consumers and to keep health care costs down.